Stevens-Johnson Syndrome After Armodafinil Use

Area of Science:

• Pharmacovigilance
• Dermatology
• Neurology

Background:

• Armodafinil is prescribed for sleep disorders.
• Stevens-Johnson syndrome (SJS) is a rare but severe adverse drug reaction.
• The association between armodafinil and SJS requires further investigation.

Observation:

• A 21-year-old woman developed SJS shortly after initiating armodafinil therapy.
• This adverse event was not previously documented in medical literature.
• The drug's label includes SJS as a potential risk.

Findings:

• This case report provides the first documented instance of SJS linked to armodafinil.
• Post-marketing research and this case support a causal relationship.
• Early recognition and armodafinil cessation are crucial.

Implications:

• Healthcare providers should consider SJS in patients presenting with relevant symptoms after armodafinil initiation.
• Prompt diagnosis and drug withdrawal can mitigate severe morbidity and mortality.
• This finding contributes to the understanding of armodafinil's safety profile.